Background. Qingyihuaji formula (QYHJ) is a widely used herbal formula that has shown promising antitumor effect in the treatment of pancreatic cancer in the Cancer Hospital, Fudan University, Shanghai, China. Objective. This research was conducted to study whether Ski acts as a therapeutic target of QYHJ formula in the treatment of SW1990 pancreatic cancer. Methods. The expression changes of Ski mRNA and protein in SW1990 pancreatic cancer subcutaneously transplanted tumor treated with QYHJ were detected by real-time polymerase chain reaction and Western blot. Then, we established a stable transfection SW1990 cell with low expression of Ski through lentivirus-mediated RNA interference (RNAi) technique. The responses to QYHJ treatment on a subcutaneously transplanted tumor with different Ski expression statuses were evaluated. Finally, the effect of Ski downregulation on SW1990 cell biological behavior was also evaluated. Results. Expression of Ski mRNA and protein in SW1990 subcutaneously transplanted tumor decreased dramatically after the treatment with QYHJ. Stable transfection cells with low expression of Ski (SW1990/Ski RNAi) were created, and negative vector-transfected cells (SW1990/con RNAi) were used as controls. The tumor weight inhibitory rates of QYHJ on subcutaneously transplanted tumors formed by SW1990 or SW1990/con RNAi were 29.6% and 32.2%, respectively, whereas they were 16.0% to 17.8% when the tumors were formed by SW1990/Ski RNAi. Ski downregulation sensitized the response of SW1990 cells to TGF-b1-induced growth inhibition in vitro. Flow cytometric analyses revealed that the percentage of cells in the G1 phase increased from 40.4% to 62.9% when Ski was downregulated. The subcutaneously transplanted tumors formed by SW1990/Ski RNAi grew much more slowly than those formed by parental and control vector-transfected cells. Conclusion. Ski acts as therapeutic target of QYHJ in the treatment of SW1990 pancreatic cancer cells, and its expression status mediates different responses to QYHJ treatment.
Introduction
Qingyihuaji formula (QYHJ) has been used for the treatment of human pancreatic cancer for many years in the Cancer Hospital, Fudan University, Shanghai, China. Our retrospective clinical studies have suggested that treatment with QYHJ has resulted in prolonged survival time for patients with pancreatic cancer. 1, 2 Animal studies showed that QYHJ could inhibit the growth of subcutaneously transplanted pancreatic tumors in nude mice. 3 To further explore the potential mechanism of the antitumor effect or QYHJ on pancreatic cancer, a microarray analysis of gene expression profile change of human pancreatic cancer-transplanted tumor treated with or without QYHJ was introduced. The result revealed that the expression of 7 genes was downregulated after the treatment with QYHJ, including IFI44, HLA-DRB3, QSCN6, Ski, EEF2, CRMP1, and EIF2C1.
Here, we focus our major attention on the expression change of Ski because studies have shown that Ski may act as an oncogene that confers resistance to the TGF-b cytostatic response and when bound to the nuclear Smad complex on target genes, recruits corepressors of the N-CoR family and histone deacetylases, thus, blocking the positive transcriptional activity of Smads. [5] [6] [7] [8] Recent evidence has shown that expression of the oncoprotein, Ski, is evident in several human malignancies, and the magnitude of expression is correlated with tumor progression in melanoma and esophageal and colorectal cancers. [9] [10] [11] [12] [13] All these results suggest that Ski might act as a target of QYHJ treatment for pancreatic cancer. In this study, we established a human pancreatic cancer cell line SW1990 with low expression of Ski through the RNAi technique to evaluate the response to QYHJ treatment of SW1990 with different Ski expression statuses.
Materials and Methods

Cell Lines and Mice
Human pancreatic cancer cell line SW1990 was obtained from the American Type Culture Collection and grown in complete growth medium as recommended by the manufacturer. The cultured cells were maintained in a humidified 5% CO 2 atmosphere at 37°C. Female BALB/c-nu/nu nude mice, 4 to 6 week sold, were obtained from Shanghai Laboratory Animal Center, Chinese Academy of Sciences (Shanghai, China) and housed in laminar flow cabinets under specific pathogen-free conditions with food and water ad libitum. The study protocol was approved by the Shanghai Medical Experimental Animal Care Committee.
Drugs and Reagents
QYHJ was composed of Hedyotidis herba, Amorphophallus konjac, Herba scutelleriae barbatae, coix seed, akebia stem, fiveleaf gynostemma herb, and java amomum fruit. Single herb powders for each herb were produced by Jiangyin Tianjiang Pharmaceutical Co, Ltd. The final decoction of QYHJ was prepared by dissolving the herb powder into distilled water to the required concentration in the Pharmaceutical Department of Cancer Hospital, Fudan University, Shanghai, China. The daily dosage for the nude mice is 36 g/kg, which was calculated according to the following human-mouse transfer formula
, where D, R, and W represent dosage, shape coefficient, and body weight, respectively, and a and b represent human or mouse, respectively. Human recombinant TGF-b1 was obtained from Peprotech Asia (San Ramon, CA) and dissolved in 10 mM citric acid, with 2 mg/mL bovine serum albumin (BSA). Antibody against Ski was purchased from Santa Cruz Biotechnology.
Lentivirus-Mediated Ski RNA Interference
We selected 3 different sequences for targeting the Ski gene using the BLOCK-It RNAi designer (Invitrogen, Carlsbad, CA) (http://rnaidesigner.invitrogen.com/rnaiexpress/rnai Express.jsp) and finally chose the most effective interfering sequence to perform further studies. The preparation of lentiviral vectors expressing human Ski short hairpin RNA (shRNA) was performed using the SBI lentiviral expression system (catalog no. K4944-00; Invitrogen), following the manufacturer's instructions. Briefly, small interference RNA (siRNA) targeting the following sequences were synthesized and purified by Qiagen-Xeragon (Germantown, MD): Ski sense 5'-GAT GAAAGAGGCCAACGAG -3', Ski antisense 5'-CTACTTTC TCCGGTTGCTC-3'; control sense 5'-TTCTCCGAACGT GTCACGT-3', control antisense 5'-AAGAGGCTTGCACA GTGCA-3'. The target specificity of these sequences was confirmed by BLAST search (http://www.ncbi.nih.gov/ BLAST). Then, the DNA oligos were annealed and inserted in the BamH I (GGATCC) and EcoRI (GAATTC) sites of pSIH1-H1-copGFP shRNA Vector. The recombinant vectors were identified by automated sequencing analysis and then transfected into 293T cells by LipofectamineTM 2000 transfection reagent. Real-time polymerase chain reaction (PCR) was used for selection of the most effective Ski silencing sequence. Next, according to the instructions of the SBI Lentivector expression system, a lentiviral expression construct and pPACK packaging plasmid mix were cotransfected into 293T cells. Then, viral particles were collected, and the titer was determined. The recombinant lentivector were used for infecting the target cell. The pancreatic cell line SW1990 was exposed to lentivirus-containing supernatant for 16 hours in the presence of 6 mg/mL Polybrene (Sigma). Pooled stable transfectants were established using puromycin selection.
Cell Proliferation Assays
A total of 5 × 10 3 cells was plated in duplicate wells of 96-well plates and allowed to adhere overnight. Cells were then treated with human recombinant TGF-b1 at concentrations ranging from 0 to 300 pM. After 48 hours, indices of cell proliferation were determined with Cell Counting Kit-8 (Dojindo. Molecular Technologies, Inc, Gaithersburg, MD).
Cell Cycle Analysis
For cell cycle analysis of cells, cells growing at low density (40%) in normal growth medium were treated with TGF-b1 (200 pM) or vehicle. After 24 h, cells were fixed with 1% paraformaldehyde in PBS (phosphate-buffered saline) for 15 minutes and refixed with 70% ethanol. The cells were then treated following the standardized protocol, and cell cycle analyses were done by flow cytometry as described previously. 
Assessment of Tumorigenicity In Vivo
Reverse Transcription Polymerase Chain Reaction Analysis
Total RNA was extracted from cultured cells using TRIzol Reagent (Invitrogen, San Diego, CA, USA) and reverse transcription PCR (RT-PCR) were performed according to the manufacturer's instructions (MBI Fermentas, Vilnius, Lithuania). Gene-specific primers for the human Ski gene (forward, 5'-ACCGTGCCTATTACCAAGCG-3'; reverse, 5'-TCCA GCAAGCAGAGGACCAG-3'; 156 bps) were synthesized at Shanghai Sangon Biological Engineering & Technology Services Co (Shanghai, China). All experiments were repeated at least 3 times, and the GAPDH (glyceraldehyde-3-phosphate dehydrogenase) gene (forward, 5'-GGGAGC CAAAAGGGTCATCATCTC-3'; reverse, 5'-CCATGCCA GTGAGCTTCCCGTTC-3'; 353 bps) was chosen as an internal control. We used SYBR green I (Roche Diagnostics) to perform quantitative real-time RT-PCR analyses of mRNA levels for the human genes encoding Ski.
Western Blot Analysis
Cells were washed twice with ice-cold PBS and scraped into 1 mL of ice-cold NP40 lysis buffer (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% (v/v) NP40, 1 mM EDTA, 50 mM NaF, 5 mM Na PPI,1 mM phenylmethylsulfonyl fluoride, 1 mg/mL leupeptin, and 1 mg/mL pepstatin A). Cells were then sonicated for 5 s at 5 W. Insoluble debris was removed by centrifugation at 1000 g for 15 minutes. Total proteins (50 mg) were analyzed by 10% SDS-PAGE. Western blot was performed according to standard protocols. 16 Blot quantitation was done with a Molecular Dynamics Laser Densitometer (Model PSD) and the Image Quant Version 1 software.
Statistical Analysis
The data were expressed as mean ± standard deviation. ANOVA and Student's t test were used to determine the statistical significance of differences between experimental groups, with P < .05 as the statistically significant level. treatment with QYHJ decreased by 39.6% and 41.3% of that in the untreated group, respectively ( Figure 2 ). This result suggests that Ski expression in SW1990 subcutaneously transplanted tumor, both at mRNA and protein levels, was significantly reduced after the treatment with QYHJ.
Results
Ski Expression Was Downregulated, Accompanied by Slowed Tumor Growth, When SW1990 Tumors Were Treated With QYHJ
Generation of SW1990 Pancreatic Cancer Cells With Different Ski Expressions
Our study has shown that QYHJ treatment resulted in reduced expression of Ski. To make sure whether Ski acted as a therapeutic target of QYHJ on SW1990 pancreatic cancer cells, we applied a lentivirus-mediated RNAi approach to establish SW1990 cells with downregulated Ski expression ( Figure 3 ). Quantitative real-time PCR and Western blot analysis of clones for each construct revealed that the expression of Ski mRNA and protein in SW1990/con RNAi and SW1990/Ski RNAi were 105%, 123%, 46%, and 30%, respectively, of that in parental cells (Figure 4 ).
Different Expressions of Ski Mediated Different Responses of SW1990 Tumors to the Treatment of QYHJ
After clarification that QYHJ treatment resulted in reduced expression of Ski and slowed tumor growth, we needed to determine whether Ski mediated different responses of SW1990 tumors to treatment with QYHJ. We further studied the effect of QYHJ on subcutaneously transplanted tumors with different Ski expression statuses. We found that the tumor weight IR of QYHJ on subcutaneously transplanted tumor formed by SW1990 or SW1990/con RNAi were 29.6% and 32.2%, respectively, whereas it was 16.0% to 17.8% when the tumors were formed by SW1990/Ski RNAi ( Figure 5 ). growth of parental and control RNAi SW1990 cells that expressed high levels of Ski was resistant to the inhibitory effects of TGF-b1. In contrast, SW1990/Ski RNAi cells, which expressed low levels of Ski, were inhibited up to 40% when exposed to TGF-b1 ( Figure 6A ). The TGF-b1-induced cell proliferative inhibition began at a much lower level of 25 pM. Next, we investigated whether downregulation of Ski could affect the growth of pancreatic cancer cells in nude mice. As shown in Figure 6C , all mice injected with pancreatic cancer cells developed subcutaneous tumors. That means downregulation of Ski did not alter the frequency of tumor development (tumorigenicity) of the SW1990 cell line. Tumors formed by RNAi SW1990 were, however, much smaller than those formed by parental and control RNAi cells ( Figure 6B and 6C) . Taken together, these data clearly showed that downregulation of Ski could inhibit the growth of SW1990 cell both in vitro and in vivo.
Downregulation of Ski Inhibited Growth of SW1990 Both In Vitro and In Vivo
Downregulation of Ski Enhanced TGF-b1-Induced G1 Phase Arrest
Flow cytometric analyses revealed that the percentage of Ski downregulated cells in the G1 phase dramatically increased from 40.4% to 62.9%, with reduction of S phase from 24.8% to 12.7% when induced by TGF-b1 ( Figure 7 ).
Discussion
Pancreatic cancer remains one of the leading causes of cancer deaths both in China and abroad. 17 In Shanghai, China, the incidence rate of pancreatic cancer increased during 1972 to 1999 by 2% annually in both sexes. 18 Surgical resection remains the only definitive chance for long-term survival, but only 10% to 20% of patients with pancreatic adenocarcinoma present with resectable disease. 17 Therefore, the majority of patients presenting with advanced local-regional or metastatic disease will be treated with chemotherapy and/or radiation therapy with a potential 3-to 6-month survival benefit and an overall 5-year survival rate of less than 5%. 17 Traditional Chinese medicine (TCM) has been widely used for cancer treatment in China for thousands of years. In the past years, application of integrative TCM and Western medicine to pancreatic cancer treatment has shown promising results in our department. Our retrospective clinical studies have shown the efficiency of QYHJ, a TCM formula, in the treatment of pancreatic cancer. 1,2 However, the exact mechanism remains unknown. In one of our previous studies, we examined the gene expression profile change after QYHJ treatment. We found that 7 genes were downregulated, and these are involved in tumor cell proliferation, invasion, metastasis, and so on. We focused our attention on Ski because many studies have shown that Ski acts as an oncogene. This finding suggested that the slowed tumor growth correlated with the downregulated expression of Ski. But we were not sure whether Ski downregulation after QYHJ treatment could result in reduced tumor growth, and whether there was a cause-and-effect relationship between tumor growth inhibition and QYHJ treatment remained unclear. So we hypothesized that if Ski was a potential target of QYHJ treatment, the anticancer effect of QYHJ would be compromised when this potential target was silenced. To confirm our speculation, we generated SW1990 pancreatic cancer cells with low expression of Ski, through RNAi techniques, attempting to understand whether different Ski expressions can result in different antitumor effects of QYHJ on SW1990 cancer cells. Consistent with our speculation, the tumor IR of QYHJ decreased from 32.2% to 16% when Ski expression was downregulated. This result suggested that Ski was one of the important targets of QYHJ treatment on pancreatic cancer cells SW1990. The expression status of Ski mediated different responses of pancreatic cancer to QYHJ treatment, indicating that detection of Ski expression may be used for predicting the response of pancreatic cancer to QYHJ treatment; therefore, we could choose patients who would benefit more from QYHJ treatment, thus, avoiding unnecessary treatment. Although Ski used to be identified as an oncogene and correlated to patients' prognosis in some cancer types, its exact function remains unknown, especially in pancreatic cancer. In this study, we also evaluated the role Ski plays in pancreatic cancer. We found that downregulation of Ski could inhibit the growth of SW1990 cells both in vitro and in vivo. The inhibitory effect of Ski was involved in enhanced TGF-b1-induced G1 phase arrest, which is consistent with results in one of our previous studies, in which QYHJ treatment resulted in decreased percentage of S phase cells and increased G0-G1 phase cells, suggesting that QYHJ treatment led to the G1 phase arrest of pancreatic cancer. 3 Attempts to improve outcome in patients treated with Chinese herbal medicine have conventionally been based on seeking for an optimal combination or optimal dosages of herbal prescription. A fixed-composition, rational, and effective TCM prescription may bring benefit to most patients; however, there is a significant proportion of patients who may derive little or no benefit from the same prescription. The mechanism underlying this diversity of response remains unclear. Recently, gene expression profiling has been widely used to discriminate the prognosis, to predict response to therapy, and to define the most suitable treatment. This provided us with the new idea that gene expression profiling may be used for identification of responders and nonresponders to TCM treatment. According to our results, Ski expression status was associated with the response rate of pancreatic cancer to the treatment of QYHJ. Our study provides a new perspective for improving the effect of TCM treatment-that is, gene expression profiling may represent a unique and powerful tool for the identification of responders and nonresponders to TCM therapy.
Conclusion
QYHJ inhibited the growth of human pancreatic cancer cell SW1990, partly through downregulation of Ski expression. Ski acts as a therapeutic target of QYHJ in the treatment of SW1990 pancreatic cancer cells, and its expression status mediates different responses to QYHJ treatment of SW1990 pancreatic cancer cells.
